News

In this discussion with Chilukuri, the most notable highlights from his DERM 2025 session ‘Skincare Secrets and Quick Fixes’ were covered.

In this interview, Friedman highlights notable points from his DERM 2025 talk on managing patients with tinea.

Combination therapy results in an overall reduction in 1-year mortality and hospitalizations compared to patients receiving SGLT2 inhibitors alone.

In a new interview at the DERM2025 Conference, Boswell highlights a session on systemic drugs and another session on wart and molluscum imitators.

In a new interview at the DERM2025 Conference, Stein Gold highlighted several topical options for patients with psoriasis outside of topical steroids.

This interview with Friedman highlights the takeaways from his DERM 2025 session on managing chronic pruritus in dermatology.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

An analysis of data from the LUNA 3 trial indicated the comparative safety and clinical significance of the IWG criteria versus the standard platelet count threshold.

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.

FDA approval of topical delgocitinib marks a long-awaited treatment milestone for adults with chronic hand eczema.

Although shown to have no connection to autism in multiple studies, the mercury-based agent will no longer be included in multidose influenza shots.

Holden describes the importance of including SLD in global health policy frameworks and how a side event at the 78th WHA sought to address current gaps.

A new analysis found a 0.78% prevalence of CSU in US adults, exceeding earlier estimates, and revealed significant mental, physical, and work-related burdens.

A review of data from an ongoing phase 3 trial indicates the potential for a generalized, prespecified fitusiran treatment for hemophilia A and B.

RSV hospitalizations in older adults lead to worse health outcomes and increased cardiovascular risks, highlighting the need for vaccination and monitoring.

FDA approves delgocitinib cream, offering a new treatment option for adults with moderate-to-severe chronic hand eczema.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Sanyal describes the growing burden of SLD and its connection to other major chronic diseases, underscoring the need for better recognition and prevention efforts.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

Post-COVID CT guidance favors low-dose imaging, clear terms, and precise timing.

Positive topline results showed obefazimod met its primary endpoint for clinical remission at week 8 in the 50 mg dose cohort in ABECT-1 and ABECT-2.

In children with mild immediate or delayed reactions, direct drug provocation testing may eliminate the need for painful skin tests, according to new data from Türkiye.